Clinical Trial Update: A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating TAS-102 (Lonsurf) in metastatic bladder cancer resistant to platinum therapy and checkpoint inhibitors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Lonsurf (trifluridine/tipiracil)

Snippet

Sponsor: Rahul Parikh | Conditions: Bladder Cancer | Phase 2 | Status: UNKNOWN